Appendix

Appendix Table 1. The Twelve RXCs Included in the 2018 HHS-HCC Model.

Prescription Drug Category (RXC)	Use	Condition
Anti-HIV agents	Imputation and severity	HIV
Anti-hepatitis c (HCV) agents	Imputation and severity	Hepatitis C
Antiarrhythmics	Imputation and severity	Heart arrhythmia
Phosphate binders	Imputation and severity	Chronic kidney disease
Inflammatory bowel disease agents	Imputation and severity	Inflammatory bowel disease
Insulin	Imputation and severity	Diabetes
Anti-diabetic agents, except insulin	Imputation and severity	Diabetes
and metformin		
Multiple sclerosis agents	Imputation and severity	Multiple Sclerosis
Immune suppressants and	Imputation and severity	Inflammatory bowel
immunomodulators		disease, rheumatoid
		arthritis, and lupus
Cystic fibrosis agents	Imputation and severity	Cystic fibrosis
Ammonia detoxicants	Severity-only	N/A
Diuretics, loop and select	Severity-only	N/A
potassium-sparing		

Source: HHS Notice of Benefit and Payment Parameters for 2018 (CMS, 2016c).


Notes: The last two RXCs were excluded from our analyses.

Appendix Table 2. Comparison of Risk Score Increases under the 2017 and the 2018 HHS-HCC Models for an Enrollee in Various Scenarios.

	HIV		Multiple Sclerosis		
	2017 Model	2018 Model	2017 Model	2018 Model	
HCC only	8.450	0.409	13.194	6.087	
RXC only	N/A	6.050	N/A	16.192	
Both HCC and RXC	8.450	8.862	13.194	19.105	

Source: HHS Notices of benefit and payment parameters for benefit years 2017 and 2018 (CMS, 2016b; CMS, 2016c).

Notes: This table uses HIV and multiple sclerosis as two examples to illustrate risk score increases in various scenarios for a gold plan enrollee. Under the 2018 HHS-HCC model, an individual with both the HCC and the RXC receives an additional interaction term, whose coefficient can be either positive or negative. In the case of HIV, the score of the interaction term is 2.403, and thus under the 2018 model, an individual with both the HCC and the RXC receives a score of 8.862 (0.409+6.050+2.403). The case of multiple sclerosis is similar, except that the interaction term has a negative coefficient (-3.174).



Appendix Figure 1. RXC-only patients' status in the previous year (2016).

Source: Authors' analysis of the 2016 and 2017 member information file, medical claims, and pharmacy claims from the Optum data.

Notes: The sample includes enrollees with any of the six conditions who in 2017 only had the associated prescription drug categories (RXCs) and who continuously enrolled in plans offered by the insurer in both 2016 and 2017. HCC stands for hierarchical condition category.

Appendix Table 3. Partial-year Enrollees Who Would Have Received RXCs and Who Would Not under the 2018 HHS-HCC Model.

	Months Enrolled			Full-Year	
	1-3	4-6	7-9	10-11	Enrollees
0 HCCs	93.15%	87.33%	81.96%	82.24%	79.62%
0 HCC and only unassociated RXC(s)	0.79%	0.58%	0.45%	0.36%	0.34%
1 HCC	4.12%	7.87%	10.81%	10.98%	12.39%
1 HCC and only associated RXC(s)	0.80%	1.75%	2.75%	2.27%	2.83%
1 HCC and only unassociated RXC(s)	0.04%	0.07%	0.10%	0.10%	0.12%
2 HCCs	0.57%	1.20%	1.86%	1.99%	2.31%
2 HCCs and only associated RXC(s)	0.17%	0.42%	0.78%	0.67%	0.87%
2 HCCs and only unassociated RXC(s)	0.01%	0.01%	0.02%	0.02%	0.03%
3+ HCCs	0.25%	0.51%	0.77%	0.86%	0.92%
3+ HCCs and only associated RXC(s)	0.08%	0.23%	0.46%	0.46%	0.52%
3+ HCCs and only unassociated RXC(s)	0.00%	0.01%	0.02%	0.02%	0.02%
N	1,147,274	1,018,063	1,117,051	454,150	5,162,983

Source: Authors' analysis of the 2017 member information file, medical claims, and pharmacy claims from the Optum data.

Notes: The sample includes commercially insured partial-year enrollees ages 21 to 64 that did not switch plans in 2017. A hierarchical condition category (HCC) Group was counted as one single HCC. The two severity-only prescription drug categories (RXCs) were excluded from the analysis. Individuals with "associated RXC(s)" were those taking medications in RXC(s) associated with the HCC(s) they already had. Individuals with "unassociated RXC(s)" were those taking medications in RXC(s) not associated with the HCC(s) they had. By definition, individuals with zero HCCs did not receive associated RXCs. Enrollee subgroups with both associated and unassociated RXCs were excluded due to small group size.

Appendix Table 4. Mean Age by Level of Plan Spending of Enrollees with 0 HCCs Only under the 2018 HHS-HCC Model.

	Men	Women	N	% Women
Plan spending=0	38.0	39.9	1,032,168	30%
Plan spending between 0 and \$500	40.8	40.6	1,292,949	41%
Plan spending between \$500 and \$2,000	43.6	42.1	948,027	62%
Plan spending greater than \$2,000	45.5	44.3	837,731	58%

Source: Authors' analysis of the 2017 member information file, medical claims, and pharmacy claims from the Optum data.

Notes: The sample includes enrollees with 0 HCCs only under the 2018 HHS-HCC Model. All spending is in 2017 dollars.

Appendix Table 5. Top 15 Diagnoses by Share of Patients for Enrollees with 0 HCCs Only under the 2018 HHS-HCC Model.

Diagnosis   ICD-10   % With this Dx   Diagnosis   ICD-10   % With this Dx	All Enrollees with 0 HCCs Only			Enrollees with 0 HCCs Only and with Pla	n Spending	g>\$2,000
No diagnosis (includes those with no medical claims)  Encounter for general adult medical examination without abnormal findings  Encounter for general adult medical examination without abnormal findings  Encounter for general adult medical examination without abnormal findings  Encounter for general adult medical examination without abnormal findings  Encounter for gynecological examination (general) (routine) without abnormal findings  Encounter for gynecological examination (general) (routine) without abnormal findings  Essential (primary) hypertension  I10 11% Encounter for immunization Z23 15% Encounter for immunization  Encounter for immunization  Encounter for screening for malignant neoplasm of colon  Acute upper respiratory infection, unspecified  Hyperlipidemia, unspecified  E785 5% Gastro-esophageal reflux disease without esophagitis  Acute pharyngitis, unspecified  F419 9% Anxiety disorder, unspecified  F419 4% Other fatigue  R5383 4% Cough  R5383 9% Witamin D deficiency, unspecified  R5383 9% Witamin D deficiency, unspecified  R5383 9% Witamin D deficiency, unspecified  E559 8% without esophagitis	Diagnosis	ICD-10	% With	Diagnosis ICD-10		% With
Encounter for general adult medical examination without abnormal findings   Encounter for general adult medical examination without abnormal findings   Encounter for gynecological examination without abnormal findings   Encounter for gynecological examination (general) (routine) without abnormal findings   Essential (primary) hypertension   T10   22%   Essential (primary) hypertension   T10   22%   Essential (primary) hypertension   T10   11%   Encounter for immunization   Z23   15%   Encounter for immunization   Z23   9%   Lower back pain   M545   14%   Encounter for screening for malignant neoplasm of colon   E785   T1%   E785   T			this Dx			this Dx
Encounter for general adult medical examination without abnormal findings  Encounter for gynecological examination (general) (routine) without abnormal findings  Encounter for gynecological examination (general) (routine) without abnormal findings  Essential (primary) hypertension  Essential (primary) hypertension  I10		N/A	28%	Encounter for general adult medical	Z0000	33%
Encounter for gynecological examination (general) (routine) without abnormal findings  Encounter for gynecological examination (general) (routine) without abnormal findings  Essential (primary) hypertension  Essential (primary) hypertension  I10 11% Encounter for immunization  Encounter for screening for malignant neoplasm of colon  Acute upper respiratory infection, unspecified  Hyperlipidemia, unspecified  E785 5% Gastro-esophageal reflux disease  Without esophagitis  Acute pharyngitis, unspecified  E785 5% Anxiety disorder, unspecified  E785 9%  Cough  Encounter for screening for malignant respiratory infection, unspecified  E785 5% Anxiety disorder, unspecified  E785 9%  Cough  Encounter for screening for malignant respiratory infection, unspecified  E785 9%  Anxiety disorder, unspecified  E785 9%  Cough  E785 9%  Cough  E785 9%  Gastro-esophageal reflux disease  E786 11%  Cough  E787 9%  Acute upper respiratory infection, unspecified  E788 9%  Cough  E788 9%  Cough  E788 9%  Cough  E789 9%  Cough  Cough	medical claims)			examination without abnormal findings		
Encounter for gynecological examination (general) (routine) without abnormal findings  Essential (primary) hypertension  Essential (primary) hypertension  I10 11% Encounter for immunization  Essential (primary) hypertension  I10 11% Encounter for immunization  Z23 15%  Encounter for immunization  Acute upper respiratory infection, unspecified  Hyperlipidemia, unspecified  E785 5% Gastro-esophageal reflux disease without esophagitis  Acute upper respiratory infection, unspecified  E785 5% Anxiety disorder, unspecified  E1211 4% Acute upper respiratory infection, unspecified  E785 5% Acute upper respiratory infection, unspecified  E785 5% Anxiety disorder, unspecified  E785 5% Acute upper respiratory infection, unspecified  E785 5% Acute upper respir	Encounter for general adult medical	Z0000	22%	Encounter for gynecological	Z01419	24%
Encounter for gynecological examination (general) (routine) without abnormal findings  Essential (primary) hypertension  I10	examination without abnormal findings			examination (general) (routine) without		
examination (general) (routine) without abnormal findings  Essential (primary) hypertension  Encounter for immunization  Encounter for screening for malignant neoplasm of colon  Acute upper respiratory infection, unspecified  Hyperlipidemia, unspecified  E785  Formula Gastro-esophageal reflux disease without esophagitis  Acute pharyngitis, unspecified  E785  Formula Gastro-esophageal reflux disease without esophagitis  Acute upper respiratory infection, unspecified  E785  Formula Gastro-esophageal reflux disease without esophagitis  Acute upper respiratory infection, unspecified  E785  Formula Gastro-esophageal reflux disease without esophagitis  Acute upper respiratory infection, unspecified  Formula Gastro-esophageal reflux disease  Formula Gastro-esophageal r				abnormal findings		
abnormal findings  Essential (primary) hypertension  Encounter for immunization  Encounter for screening for malignant neoplasm of colon  Acute upper respiratory infection, unspecified  Hyperlipidemia, unspecified  E785  Gastro-esophageal reflux disease  Without esophagitis  Acute upper respiratory infection  B785  B786  Anxiety disorder, unspecified  E785  E785  Anxiety disorder, unspecified  E785  Anxiety disorder, unspecified  E785  E785  Anxiety disorder, unspecified  E785  Anxiety disorder, unspecified  E785		Z01419	14%	Essential (primary) hypertension	I10	22%
Essential (primary) hypertension I10 11% Encounter for immunization Z23 15% Encounter for immunization Z23 9% Lower back pain M545 14% Lower back pain M545 6% Encounter for screening for malignant neoplasm of colon Hyperlipidemia, unspecified E785 5% Gastro-esophageal reflux disease without esophagitis without esophageal reflux disease R5383 4% Cough R5383 4% Cough R5383 9% Gastro-esophageal reflux disease R5383 9% Without esophagitis						
Encounter for immunizationZ239%Lower back painM54514%Lower back painM5456%Encounter for screening for malignant neoplasm of colonZ121113%Acute upper respiratory infection, unspecifiedJ0696%Hyperlipidemia, unspecifiedE78511%Hyperlipidemia, unspecifiedE7855%Gastro-esophageal reflux disease without esophagitisK21911%Acute pharyngitis, unspecifiedJ0295%Neck painM54210%CoughR055%Anxiety disorder, unspecifiedF4199%Encounter for screening for malignant neoplasm of colonZ12114%Acute upper respiratory infection, unspecifiedJ0699%Other fatigueR53834%CoughR059%Anxiety disorder, unspecifiedF4194%Other fatigueR53839%Gastro-esophageal reflux diseaseK2194%Vitamin D deficiency, unspecifiedE5598%without esophagitisE5598%						
Lower back pain  M545 6% Encounter for screening for malignant neoplasm of colon  Acute upper respiratory infection, unspecified  Hyperlipidemia, unspecified  E785 5% Gastro-esophageal reflux disease without esophagitis  Acute pharyngitis, unspecified  J029 5% Neck pain  M542 10%  Acute upper respiratory infection, without esophagitis  Acute pharyngitis, unspecified  E785 5% Anxiety disorder, unspecified  F419 9% Acute upper respiratory infection, unspecified  Other fatigue  R5383 4% Cough Anxiety disorder, unspecified  R5383 9%  Gastro-esophageal reflux disease  K219 11%  M542 10%  Acute upper respiratory infection, unspecified  Cough Acute upper respiratory infection, unspecified  Other fatigue  R5383 9%  Gastro-esophageal reflux disease  K219 4% Vitamin D deficiency, unspecified  E559 8%  Without esophagitis		I10	11%	Encounter for immunization	Z23	15%
Acute upper respiratory infection, unspecified  Hyperlipidemia, unspecified  E785  Gastro-esophageal reflux disease without esophagitis  Acute pharyngitis, unspecified  J029  R05  S%  Anxiety disorder, unspecified  T1211  Acute upper respiratory infection, unspecified  F419  Acute upper respiratory infection, unspecified  T21211  T2	Encounter for immunization	Z23	9%			
Acute upper respiratory infection, unspecified  Hyperlipidemia, unspecified  E785  E785  S%  Gastro-esophageal reflux disease without esophagitis  Acute pharyngitis, unspecified  F419  Encounter for screening for malignant neoplasm of colon  Other fatigue  Anxiety disorder, unspecified  R5383  F49  Cough  R5383  F49  Cough  Anxiety disorder, unspecified  R5383  F419  Cough  Anxiety disorder, unspecified  Cough  Anxiety disorder, unspecified  R5383  F49  Cough  Anxiety disorder, unspecified  Cough  Anxiety disorder, unspecified  R5383  F419  Cough  Anxiety disorder, unspecified  Cough  Anxiety disorder, unspecified  R5383  F419  Cough  Anxiety disorder, unspecified  R5383  F419  Cough  Anxiety disorder, unspecified  Cough  Anxiety disorder, unspecified  R5383  F419  Cough  Cough  Anxiety disorder, unspecified  Cough	Lower back pain	M545	6%		Z1211	13%
unspecifiedE7855%Gastro-esophageal reflux disease without esophagitisK21911%Acute pharyngitis, unspecifiedJ0295%Neck painM54210%CoughR055%Anxiety disorder, unspecifiedF4199%Encounter for screening for malignant neoplasm of colonZ12114%Acute upper respiratory infection, unspecifiedJ0699%Other fatigueR53834%CoughR059%Anxiety disorder, unspecifiedF4194%Other fatigueR53839%Gastro-esophageal reflux diseaseK2194%Vitamin D deficiency, unspecifiedE5598%without esophagitisWitamin D deficiency, unspecifiedE5598%				*		
Hyperlipidemia, unspecified E785 5% Gastro-esophageal reflux disease without esophagitis  Acute pharyngitis, unspecified J029 5% Neck pain M542 10%  Cough R05 5% Anxiety disorder, unspecified F419 9%  Encounter for screening for malignant neoplasm of colon The fatigue R5383 4% Cough R05 9%  Anxiety disorder, unspecified R5383 9%  Anxiety disorder, unspecified R5383 9%  Gastro-esophageal reflux disease K219 4% Vitamin D deficiency, unspecified E559 8%  without esophagitis		J069	6%	Hyperlipidemia, unspecified	E785	11%
Acute pharyngitis, unspecified J029 5% Neck pain M542 10%  Cough R05 5% Anxiety disorder, unspecified F419 9%  Encounter for screening for malignant neoplasm of colon Unspecified R5383 4% Cough R05 9%  Anxiety disorder, unspecified R5383 4% Cough R05 9%  Anxiety disorder, unspecified R5383 9%  Gastro-esophageal reflux disease K219 4% Vitamin D deficiency, unspecified E559 8%  without esophagitis						
Acute pharyngitis, unspecifiedJ0295%Neck painM54210%CoughR055%Anxiety disorder, unspecifiedF4199%Encounter for screening for malignant neoplasm of colonZ12114%Acute upper respiratory infection, unspecifiedJ0699%Other fatigueR53834%CoughR059%Anxiety disorder, unspecifiedF4194%Other fatigueR53839%Gastro-esophageal reflux disease without esophagitisK2194%Vitamin D deficiency, unspecifiedE5598%	Hyperlipidemia, unspecified	E785	5%	1 0	K219	11%
CoughR055%Anxiety disorder, unspecifiedF4199%Encounter for screening for malignant neoplasm of colonZ12114%Acute upper respiratory infection, unspecifiedJ0699%Other fatigueR53834%CoughR059%Anxiety disorder, unspecifiedF4194%Other fatigueR53839%Gastro-esophageal reflux disease without esophagitisK2194%Vitamin D deficiency, unspecifiedE5598%				without esophagitis		
Encounter for screening for malignant neoplasm of colon  Other fatigue  Anxiety disorder, unspecified  R5383  F419  Without esophagitis  Acute upper respiratory infection, unspecified  Cough	Acute pharyngitis, unspecified	J029	5%	±	M542	10%
neoplasm of colonunspecifiedOther fatigueR53834%CoughR059%Anxiety disorder, unspecifiedF4194%Other fatigueR53839%Gastro-esophageal reflux disease without esophagitisK2194%Vitamin D deficiency, unspecifiedE5598%		R05	5%		F419	9%
Other fatigueR53834%CoughR059%Anxiety disorder, unspecifiedF4194%Other fatigueR53839%Gastro-esophageal reflux disease without esophagitisK2194%Vitamin D deficiency, unspecifiedE5598%	Encounter for screening for malignant	Z1211	4%	Acute upper respiratory infection,	J069	9%
Anxiety disorder, unspecified F419 4% Other fatigue R5383 9% Gastro-esophageal reflux disease K219 4% Vitamin D deficiency, unspecified E559 8% without esophagitis	neoplasm of colon			unspecified		
Gastro-esophageal reflux disease K219 4% Vitamin D deficiency, unspecified E559 8% without esophagitis	Other fatigue	R5383	4%	Cough	R05	9%
without esophagitis	Anxiety disorder, unspecified	F419	4%	Other fatigue	R5383	9%
	Gastro-esophageal reflux disease	K219	4%	Vitamin D deficiency, unspecified	E559	8%
Vitamin D deficiency, unspecified E559 4% Acute pharyngitis, unspecified J029 8%	without esophagitis					
	Vitamin D deficiency, unspecified	E559	4%	Acute pharyngitis, unspecified	J029	8%

Source: Authors' analysis of the 2017 member information file, medical claims, and pharmacy claims from the Optum data.

Notes: The sample includes enrollees with 0 HCCs only under the 2018 HHS-HCC Model.

Appendix Table 6. Comparison of Sample Characteristics of the Study Sample and the Adult Calibration Sample for the 2014 HHS-HCC Model.

	Study Sample	Calibration Sample
Men 21 to 24	4.2%	3.8%
Men 25 to 29	5.4%	4.3%
Men 30 to 34	6.2%	4.8%
Men 35 to 39	6.4%	5.2%
Men 40 to 44	6.0%	5.6%
Men 45 to 49	6.3%	6.0%
Men 50 to 54	6.1%	6.2%
Men 55 to 59	5.9%	5.8%
Men 60+	4.8%	5.8%
Women 21 to 24	3.9%	4.0%
Women 25 to 29	4.9%	4.7%
Women 30 to 34	5.7%	5.3%
Women 35 to 39	6.0%	5.6%
Women 40 to 44	5.6%	6.1%
Women 45 to 49	6.0%	6.7%
Women 50 to 54	5.9%	7.0%
Women 55 to 59	5.8%	6.5%
Women 60+	4.6%	6.5%
With 0 HCCs	80.0%	80.8%
With 1 HCC	15.3%	15.2%
With 2+ HCCs	4.7%	4.0%
N	5,162,983	14,220,503

Source: The study sample column is form authors' analysis of the 2017 member information file, medical claims, and pharmacy claims from the Optum data. The calibration sample column is reported in Kautter et al. (2014).

Notes: The sample includes commercially insured enrollees ages 21 to 64 that enrolled for the full year and did not switch plans in 2017. A hierarchical condition category (HCC) Group was counted as one single HCC.